PERRY DRUG HAS MORE AUTO PARTS UNITS THAN DRUG STORES
Executive Summary
PERRY DRUG HAS MORE AUTO PARTS UNITS THAN DRUG STORES following Perry's acquisition of 46 Corvair discount auto parts stores. The acquisition of the Columbus, Ohio-based auto chain with annual sales of approximately $22 mil. will raise the number of auto stores operated by Perry to 150, compared with 143 drug stores, according to an Oct. 10 release announcing a definitive agreement between the two firms. The acquisition is the fifth by Perry in as many months, and the third purchase of an auto parts chain since June. Automotive sales are expected to account for as much as 22% of total sales for Perry in fiscal 1984, which ends Oct. 31, a company spokesman told "The Pink Sheet." Last year, net automotive sales were $40.1 mil., representing 14% of Perry's total net sales of $200.2 mil. Rx volume remains a key segment in Perry's sales mix, however. In 1983, Rx sales increased 35% to $56.4 mil., representing approximately 20% of total sales. Rx and automotive sales combined are expected to account for between 40% to 43% of total sales in fiscal 1984. According to a company spokesman, Perry's goal is for combined automotive and Rx sales to reach 50% of the chain's total sales within the next few years.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth